The Filings Report

Protagonist Therapeutics, Inc

PTGXNasdaqCIK 1377121Healthcare / Drug Manufacturersfiscal year ends December47 quarters since 2015

Revenue, Q3 FY2026
$274M
+5723.6% on Q3 FY2025
Net income
$220M
+659.3% on Q3 FY2025
Free cash flow
−$23M
−1058.4% on Q3 FY2025
Diluted EPS
$3.07
+595.2% on Q3 FY2025
Revenue, TTM
$552M
trailing four quarters
Net margin, TTM
62.0%
net income $342M
Free cash flow, TTM
$109M
$110M less $764K capex
Cash and equivalents
$498M
long-term debt —, Sep 30, 2026
Shares, 12-month change
+4.4%
65M shares, Sep 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
—
no yield
Market value
$8.6B
at the close, buybacks

Latest quarter Q3 FY2026, filed November 6, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, Protagonist Therapeutics, Inc reported revenue of $274M, +5723.6% on Q3 FY2025, and net income of $220M (+659.3%). Operating margin was 79.6%. Free cash flow, operating cash flow less capital expenditures, was −$23M (−$23M less $237K). Diluted earnings per share were $3.07.

Share price

Daily candlesticks from November 11, 2024 to November 6, 2026, with each earnings release marked; a release after the close marks the day it came out, so its reaction is the next candle. See this earnings season for every company’s reaction.

PTGX daily priceSplit-adjusted, US dollars; an earnings release
Nov 6, 2026O $135.26 · H $138.40 · L $128.00 · C $132.04 · −2.38% on the dayOver the range: +65.51%, Nov 7, 2025 to Nov 6, 2026
$72$95$119$142$166Nov 25Jan 26Apr 26Jun 26Aug 26Nov 26

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of November 6, 2026.

Revenue and net incomeRevenueNet income
−$100M$0$100M$200M$300MQ4'22, Revenue: $0Q4'22, Net income: −$34MQ4'22Q1'23, Revenue: $0Q1'23, Net income: −$34MQ1'23Q2'23, Revenue: $0Q2'23, Net income: −$38MQ2'23Q3'23, Revenue: $0Q3'23, Net income: −$34MQ3'23Q4'23, Revenue: $60MQ4'23, Net income: $27MQ4'23Q1'24, Revenue: $255MQ1'24, Net income: $207MQ1'24Q2'24, Revenue: $4MQ2'24, Net income: −$31MQ2'24Q3'24, Revenue: $5MQ3'24, Net income: −$33MQ3'24Q4'24, Revenue: $171MQ4'24, Net income: $132MQ4'24Q1'25, Revenue: $28MQ1'25, Net income: −$12MQ1'25Q2'25, Revenue: $6MQ2'25, Net income: −$35MQ2'25Q3'25, Revenue: $5MQ3'25, Net income: −$39MQ3'25Q4'25, Revenue: $7MQ4'25, Net income: −$44MQ4'25Q1'26, Revenue: $56MQ1'26, Net income: $4MQ1'26Q2'26, Revenue: $213MQ2'26, Net income: $163MQ2'26Q3'26, Revenue: $274MQ3'26, Net income: $220MQ3'26−$100M$0$100M$200M$300MQ4'22, Revenue: $0Q4'22, Net income: −$34MQ4'22Q1'23, Revenue: $0Q1'23, Net income: −$34MQ1'23Q2'23, Revenue: $0Q2'23, Net income: −$38MQ2'23Q3'23, Revenue: $0Q3'23, Net income: −$34MQ3'23Q4'23, Revenue: $60MQ4'23, Net income: $27MQ4'23Q1'24, Revenue: $255MQ1'24, Net income: $207MQ1'24Q2'24, Revenue: $4MQ2'24, Net income: −$31MQ2'24Q3'24, Revenue: $5MQ3'24, Net income: −$33MQ3'24Q4'24, Revenue: $171MQ4'24, Net income: $132MQ4'24Q1'25, Revenue: $28MQ1'25, Net income: −$12MQ1'25Q2'25, Revenue: $6MQ2'25, Net income: −$35MQ2'25Q3'25, Revenue: $5MQ3'25, Net income: −$39MQ3'25Q4'25, Revenue: $7MQ4'25, Net income: −$44MQ4'25Q1'26, Revenue: $56MQ1'26, Net income: $4MQ1'26Q2'26, Revenue: $213MQ2'26, Net income: $163MQ2'26Q3'26, Revenue: $274MQ3'26, Net income: $220MQ3'26−$100M$0$100M$200M$300MQ4'22, Revenue: $0Q4'22, Net income: −$34MQ1'23, Revenue: $0Q1'23, Net income: −$34MQ1'23Q2'23, Revenue: $0Q2'23, Net income: −$38MQ3'23, Revenue: $0Q3'23, Net income: −$34MQ3'23Q4'23, Revenue: $60MQ4'23, Net income: $27MQ1'24, Revenue: $255MQ1'24, Net income: $207MQ1'24Q2'24, Revenue: $4MQ2'24, Net income: −$31MQ3'24, Revenue: $5MQ3'24, Net income: −$33MQ3'24Q4'24, Revenue: $171MQ4'24, Net income: $132MQ1'25, Revenue: $28MQ1'25, Net income: −$12MQ1'25Q2'25, Revenue: $6MQ2'25, Net income: −$35MQ3'25, Revenue: $5MQ3'25, Net income: −$39MQ3'25Q4'25, Revenue: $7MQ4'25, Net income: −$44MQ1'26, Revenue: $56MQ1'26, Net income: $4MQ1'26Q2'26, Revenue: $213MQ2'26, Net income: $163MQ3'26, Revenue: $274MQ3'26, Net income: $220MQ3'26

Net income losses drawn in red.

Free cash flow
−$100M$0$100M$200M$300MQ4'22, Free cash flow: −$32MQ4'22Q1'23, Free cash flow: −$34MQ1'23Q2'23, Free cash flow: −$26MQ2'23Q3'23, Free cash flow: −$27MQ3'23Q4'23, Free cash flow: $17MQ4'23Q1'24, Free cash flow: −$28MQ1'24Q2'24, Free cash flow: $269MQ2'24Q3'24, Free cash flow: −$29MQ3'24Q4'24, Free cash flow: −$29MQ4'24Q1'25, Free cash flow: $125MQ1'25Q2'25, Free cash flow: −$30MQ2'25Q3'25, Free cash flow: −$2MQ3'25Q4'25, Free cash flow: −$37MQ4'25Q1'26, Free cash flow: −$49MQ1'26Q2'26, Free cash flow: $219MQ2'26Q3'26, Free cash flow: −$23MQ3'26−$100M$0$100M$200M$300MQ4'22, Free cash flow: −$32MQ4'22Q1'23, Free cash flow: −$34MQ1'23Q2'23, Free cash flow: −$26MQ2'23Q3'23, Free cash flow: −$27MQ3'23Q4'23, Free cash flow: $17MQ4'23Q1'24, Free cash flow: −$28MQ1'24Q2'24, Free cash flow: $269MQ2'24Q3'24, Free cash flow: −$29MQ3'24Q4'24, Free cash flow: −$29MQ4'24Q1'25, Free cash flow: $125MQ1'25Q2'25, Free cash flow: −$30MQ2'25Q3'25, Free cash flow: −$2MQ3'25Q4'25, Free cash flow: −$37MQ4'25Q1'26, Free cash flow: −$49MQ1'26Q2'26, Free cash flow: $219MQ2'26Q3'26, Free cash flow: −$23MQ3'26−$100M$0$100M$200M$300MQ4'22, Free cash flow: −$32MQ1'23, Free cash flow: −$34MQ1'23Q2'23, Free cash flow: −$26MQ3'23, Free cash flow: −$27MQ3'23Q4'23, Free cash flow: $17MQ1'24, Free cash flow: −$28MQ1'24Q2'24, Free cash flow: $269MQ3'24, Free cash flow: −$29MQ3'24Q4'24, Free cash flow: −$29MQ1'25, Free cash flow: $125MQ1'25Q2'25, Free cash flow: −$30MQ3'25, Free cash flow: −$2MQ3'25Q4'25, Free cash flow: −$37MQ1'26, Free cash flow: −$49MQ1'26Q2'26, Free cash flow: $219MQ3'26, Free cash flow: −$23MQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$200M$400M$600MQ4'22, Cash and equivalents: $126MQ4'22Q1'23, Cash and equivalents: $128MQ1'23Q2'23, Cash and equivalents: $235MQ2'23Q3'23, Cash and equivalents: $231MQ3'23Q4'23, Cash and equivalents: $187MQ4'23Q1'24, Cash and equivalents: $173MQ1'24Q2'24, Cash and equivalents: $356MQ2'24Q3'24, Cash and equivalents: $131MQ3'24Q4'24, Cash and equivalents: $97MQ4'24Q1'25, Cash and equivalents: $140MQ1'25Q2'25, Cash and equivalents: $169MQ2'25Q3'25, Cash and equivalents: $114MQ3'25Q4'25, Cash and equivalents: $128MQ4'25Q1'26, Cash and equivalents: $194MQ1'26Q2'26, Cash and equivalents: $420MQ2'26Q3'26, Cash and equivalents: $498MQ3'26$0$200M$400M$600MQ4'22, Cash and equivalents: $126MQ4'22Q1'23, Cash and equivalents: $128MQ1'23Q2'23, Cash and equivalents: $235MQ2'23Q3'23, Cash and equivalents: $231MQ3'23Q4'23, Cash and equivalents: $187MQ4'23Q1'24, Cash and equivalents: $173MQ1'24Q2'24, Cash and equivalents: $356MQ2'24Q3'24, Cash and equivalents: $131MQ3'24Q4'24, Cash and equivalents: $97MQ4'24Q1'25, Cash and equivalents: $140MQ1'25Q2'25, Cash and equivalents: $169MQ2'25Q3'25, Cash and equivalents: $114MQ3'25Q4'25, Cash and equivalents: $128MQ4'25Q1'26, Cash and equivalents: $194MQ1'26Q2'26, Cash and equivalents: $420MQ2'26Q3'26, Cash and equivalents: $498MQ3'26$0$200M$400M$600MQ4'22, Cash and equivalents: $126MQ1'23, Cash and equivalents: $128MQ1'23Q2'23, Cash and equivalents: $235MQ3'23, Cash and equivalents: $231MQ3'23Q4'23, Cash and equivalents: $187MQ1'24, Cash and equivalents: $173MQ1'24Q2'24, Cash and equivalents: $356MQ3'24, Cash and equivalents: $131MQ3'24Q4'24, Cash and equivalents: $97MQ1'25, Cash and equivalents: $140MQ1'25Q2'25, Cash and equivalents: $169MQ3'25, Cash and equivalents: $114MQ3'25Q4'25, Cash and equivalents: $128MQ1'26, Cash and equivalents: $194MQ1'26Q2'26, Cash and equivalents: $420MQ3'26, Cash and equivalents: $498MQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed November 6, 2026.

Protagonist Therapeutics, Inc income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 6, 2026Q2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 5, 2026Q4 FY2025ended Dec 31, 2025filed Feb 25, 2026Q3 FY2025ended Sep 30, 2025filed Nov 6, 2025Q2 FY2025ended Jun 30, 2025filed Aug 6, 2025Q1 FY2025ended Mar 31, 2025filed May 6, 2025Q4 FY2024ended Dec 31, 2024filed Feb 21, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue2742135675628171+5723.6%
Cost of revenue1————————
Gross profit—————————
Research and development4142474640373635+3.2%
Selling, general and administrative141313111111129+23.1%
Operating income218159(4)(50)(46)(42)(19)127+570.3%
Other income (expense)00000——0−142.4%
Pretax income2271652(44)(39)(35)(12)134+675.9%
Income tax72(2)10002—
Net income2201634(44)(39)(35)(12)132+659.3%
Diluted EPS ($)3.072.290.05—(0.62)(0.55)(0.19)—+595.2%
Diluted shares (millions)727170—646463——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed November 6, 2026.

Protagonist Therapeutics, Inc balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 6, 2026Q2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 5, 2026Q4 FY2025ended Dec 31, 2025filed Feb 25, 2026Q3 FY2025ended Sep 30, 2025filed Nov 6, 2025Q2 FY2025ended Jun 30, 2025filed Aug 6, 2025Q1 FY2025ended Mar 31, 2025filed May 6, 2025Q4 FY2024ended Dec 31, 2024filed Feb 21, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents49842019412811416914097+338.2%
Short-term investments302362354439462402435322−34.7%
Total current assets1,101807613578586603606592+87.8%
Total assets1,147886697668702718742745+63.4%
Total current liabilities5537354545363547+23.4%
Long-term debt—————————
Total liabilities6244425356505369+9.6%
Stockholders’ equity1,085842655615645668689675+68.1%
Shares outstanding (millions)6565646463626261—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed November 6, 2026.

Protagonist Therapeutics, Inc cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 6, 2026Q2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 5, 2026Q4 FY2025ended Dec 31, 2025filed Feb 25, 2026Q3 FY2025ended Sep 30, 2025filed Nov 6, 2025Q2 FY2025ended Jun 30, 2025filed Aug 6, 2025Q1 FY2025ended Mar 31, 2025filed May 6, 2025Q4 FY2024ended Dec 31, 2024filed Feb 21, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow(23)219(49)(37)(2)(29)125(29)−1098.8%
Capital expenditures00000110+169.3%
Free cash flow (CFO − capex)(23)219(49)(37)(2)(30)125(29)−1058.4%
Depreciation and amortization00000000+13.3%
Share repurchases—————————
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 25, 2026.

Income statement

Protagonist Therapeutics, Inc income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 25, 2026FY2024ended Dec 31, 2024filed Feb 21, 2025FY2023ended Dec 31, 2023filed Feb 27, 2024FY2022ended Dec 31, 2022filed Mar 15, 2023FY2021ended Dec 31, 2021filed Feb 28, 2022FY2020ended Dec 31, 2020filed Mar 10, 2021FY2019ended Dec 31, 2019filed Mar 10, 2020FY2018ended Dec 31, 2018filed Mar 12, 2019FY2017ended Dec 31, 2017filed Mar 7, 2018FY2016ended Dec 31, 2016filed Mar 7, 2017FY2015ended Dec 31, 2015filed Sep 15, 2016FY2014ended Dec 31, 2014filed Sep 15, 2016
Revenue464346027272903120———
Cost of revenue————————————
Gross profit————————————
Research and development1591381201261267565594626127
Selling, general and administrative454333322719161412732
Operating income(158)253(94)(131)(126)(65)(81)(42)(38)(33)(15)(9)
Other income (expense)0000000000——
Pretax income(129)279(79)(127)(126)(65)(78)(40)(37)(37)(15)—
Income tax140001(1)(1)0000
Net income(130)275(79)(127)(126)(66)(77)(39)(37)(37)(15)(11)
Diluted EPS ($)(2.05)4.23(1.39)(2.60)(2.71)(1.92)——————
Diluted shares (millions)646557494634——————

Balance sheet

Protagonist Therapeutics, Inc balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 25, 2026FY2024ended Dec 31, 2024filed Feb 21, 2025FY2023ended Dec 31, 2023filed Feb 27, 2024FY2022ended Dec 31, 2022filed Mar 15, 2023FY2021ended Dec 31, 2021filed Feb 28, 2022FY2020ended Dec 31, 2020filed Mar 10, 2021FY2019ended Dec 31, 2019filed Mar 10, 2020FY2018ended Dec 31, 2018filed Mar 12, 2019FY2017ended Dec 31, 2017filed Mar 7, 2018FY2016ended Dec 31, 2016filed Mar 7, 2017FY2015ended Dec 31, 2015filed Sep 15, 2016FY2014ended Dec 31, 2014filed Sep 15, 2016
Cash and equivalents1289718712612411733821062149
Short-term investments43932215511220318810047————
Total current assets5785923562433413161451381518314—
Total assets6687453582483483241551391649415—
Total current liabilities45472131444035264363—
Long-term debt——————10—————
Total liabilities53692132484575274365—
Stockholders’ equity6156753372163002808011312188(27)(13)
Shares outstanding (millions)64615851484427232117——

Cash flow statement

Protagonist Therapeutics, Inc cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 25, 2026FY2024ended Dec 31, 2024filed Feb 21, 2025FY2023ended Dec 31, 2023filed Feb 27, 2024FY2022ended Dec 31, 2022filed Mar 15, 2023FY2021ended Dec 31, 2021filed Feb 28, 2022FY2020ended Dec 31, 2020filed Mar 10, 2021FY2019ended Dec 31, 2019filed Mar 10, 2020FY2018ended Dec 31, 2018filed Mar 12, 2019FY2017ended Dec 31, 2017filed Mar 7, 2018FY2016ended Dec 31, 2016filed Mar 7, 2017FY2015ended Dec 31, 2015filed Sep 15, 2016FY2014ended Dec 31, 2014filed Sep 15, 2016
Operating cash flow58184(70)(108)(108)(72)(42)(50)4(30)(14)—
Capital expenditures211110101000
Free cash flow (CFO − capex)56183(71)(109)(109)(73)(42)(50)3(30)(15)—
Depreciation and amortization111111110000
Share repurchases————————————
Dividends paid————————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 9, 2024 to November 9, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$41M
7 sales by 2 insiders; officers and directors $41M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$95M
37 sales by 7 insiders; officers and directors $95M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Sep 30, 2026Ali AsifChief Financial Officeroption exercise9,229$38.98$360K68,232Oct 2, 2026
Sep 30, 2026Ali AsifChief Financial Officeroption exercise28,438$23.42$666K96,670Oct 2, 2026
Sep 30, 2026Ali AsifChief Financial Officeroption exercise15,650$19.19$300K112,320Oct 2, 2026
Sep 30, 2026Ali AsifChief Financial Officeroption exercise5,312$12.17$65K117,632Oct 2, 2026
Sep 30, 2026Ali AsifChief Financial Officeropen-market sale10b5-112,595$141.77$2M105,037Oct 2, 2026
Sep 30, 2026Ali AsifChief Financial Officeropen-market sale10b5-146,034$141.78$7M59,003Oct 2, 2026
Sep 10, 2026Patel Dinesh V PH DPresident and CEO, Directoroption exercise7,278$21.58$157K530,246Sep 10, 2026
Sep 10, 2026Patel Dinesh V PH DPresident and CEO, Directoropen-market sale10b5-17,278$144.10$1M522,968Sep 10, 2026
Sep 9, 2026Patel Dinesh V PH DPresident and CEO, Directoroption exercise63,548$21.58$1M586,516Sep 10, 2026
Sep 9, 2026Patel Dinesh V PH DPresident and CEO, Directoropen-market sale10b5-163,548$146.18$9M522,968Sep 10, 2026
Sep 8, 2026Patel Dinesh V PH DPresident and CEO, Directoroption exercise54,174$21.58$1M577,142Sep 10, 2026
Sep 8, 2026Patel Dinesh V PH DPresident and CEO, Directoropen-market sale10b5-154,174$145.87$8M522,968Sep 10, 2026
Sep 3, 2026Patel Dinesh V PH DPresident and CEO, Directorgift510$0.00—522,968Sep 8, 2026
Aug 11, 2026Patel Dinesh V PH DPresident and CEO, Directoroption exercise34,239$21.58$739K557,717Aug 12, 2026
Aug 11, 2026Patel Dinesh V PH DPresident and CEO, Directoropen-market sale10b5-134,239$148.52$5M523,478Aug 12, 2026
Aug 10, 2026Patel Dinesh V PH DPresident and CEO, Directoroption exercise65,761$21.58$1M589,239Aug 12, 2026
Aug 10, 2026Patel Dinesh V PH DPresident and CEO, Directoropen-market sale10b5-165,761$149.11$10M523,478Aug 12, 2026
Jun 23, 2026Waddill William D.Directoroption exercise9,000$16.54$149K16,825Jun 25, 2026
Jun 23, 2026Waddill William D.Directoropen-market sale10b5-19,000$117.94$1M7,825Jun 25, 2026
Jun 10, 2026Waddill William D.Directoroption exercise3,000$11.80$35K10,825Jun 11, 2026
Jun 10, 2026Waddill William D.Directoroption exercise6,000$16.54$99K16,825Jun 11, 2026
Jun 10, 2026Waddill William D.Directoropen-market sale10b5-19,000$107.68$969K7,825Jun 11, 2026
May 29, 2026Waddill William D.Directoroption exercise9,000$11.80$106K16,825Jun 1, 2026
May 29, 2026Waddill William D.Directoropen-market sale10b5-19,000$99.64$897K7,825Jun 1, 2026
May 12, 2026Patel Dinesh V PH DPresident and CEO, Directoroption exercise75,000$21.58$2M598,478May 14, 2026

Full insider history for Protagonist Therapeutics, Inc, or insider activity across all companies. A record of filings, not a recommendation.

Tracked funds holding it

2 of the tracked managers held PTGX in their latest 13F filing, through August 14, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded PTGX by quarter.

FundManagerQuarterValueSharesWeightMove
Duquesne Family OfficeStanley DruckenmillerQ2 2026$26M208,9000.49%added +30.8%
Baron Capital GroupRon BaronQ2 2026$2M16,0000.00%added +6.7%

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
PROTAGONIST THERAPEUTICS, INC., CIK 1377121 on EDGAR
Extract generated
November 8, 2026
Withheld
none
Repaired
4 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: other income FY2019, revenue FY2019, other income FY2023, other income FY2025
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, RevenueFromContractWithCustomerIncludingAssessedTax, Revenues
Cost of revenue: CostOfRevenue
Gross profit: not filed
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: GeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: MarketableSecuritiesCurrent
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebt
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated November 8, 2026.

JSON file
/data/financials/PTGX.json